Yuandong, Koxing... 26 pharmaceutical companies "snatching the beach" section of the board 36 on the road

225　20197，，A。，201918A，15；202042，6。，202070，400028；18，15。2021，、、、，、、36IPO，“AA”，3……。

 

、……26“”

 

2020

：、20201231

 

、2020

 

：70！400028

 

20208，，，、、，。，202025.
56～28.
06，6375%～7008%，20194000。，，，，，，，、、。，，20206122。

 

：18，15

 

20207，。，、、。，，202016.
44，119.
96%，20197.
47。，2020，。（：），，，，。，，。，，。202018.
24，92.
79%。2020，，，。，29，27，2。3010，15。

 

“AA”！3……36IPO

 

 

2021，、、、，、、36IPO。“AA”，3……。

 

 

，IPO（），200，、、、。，2016、2018，，A，3。

 

，、A，。

 

 

，，IPO。，（）、，。，、、。，，，，。，，，。1，2020，30.
18～31.
95，70%～80%，。

 

　

 

202012，IPO。，、，、POCT、。，、POCT，、。，，，、、、，，。，，、，，。，2020，17.
25～19.
84，0%～15%。

 

！、84

 

128，2021，2020，，2021。，IPO、，，；，，，；，，、、。

 

On January 29, the China Securities Regulatory Commission issued the "Regulations on the On-site Inspection of Initial Issuers"; on February 1, the Shanghai Stock Exchange issued the "Shanghai Stock Exchange Science and Technology Innovation Board Issuance and Listing Review Business Guide No.
2-Information Disclosure and Verification Requirements for Frequently Asked Questions" Self-inspection Form; On February 3, the Shanghai Stock Exchange issued the "Shanghai Stock Exchange Science and Technology Innovation Board Issuance and Listing Review Rules Application Guidelines No.
1-On-site Supervision of Sponsorship Business".
On February 5th, the China Securities Regulatory Commission issued the "Guidelines for the Application of Regulatory Rules-Information Disclosure of Shareholders of Companies Applying for Initial Listings", focusing on regulating IPO chaos such as illegal holdings, surprise shareholdings, and multi-layer nesting; on the 7th, the exchange swiftly followed Further clarify the measures and applicable connection arrangements in the issuance and listing review.
The issuer and relevant intermediary agencies responded positively, expressing that they will earnestly implement the guidelines and do a good job in information disclosure and verification.

 

　　Industry analysts pointed out that the recent frequent announcements of regulatory policies have once again sent a signal of strict supervision.
With the continuous advancement of the registration system reform on the Science and Technology Innovation Board and the Growth Enterprise Market, the new IPO policy is just right, which will help prevent the disorderly expansion of capital and improve the quality of listed companies from the source.
In 2021, the speed of listing of companies will accelerate, and the number of IPOs and the rate of IPOs will continue to remain high.

 

　　Source: Oriental Fortune.
com, China Securities Regulatory Commission, Shanghai Stock Exchange official website, company announcement

　　Medical News, February 25, July 2019, the highly-regarded Sci-tech Innovation Board started to open, detonating the A-share market.
According to statistics, in 2019, 18 pharmaceutical companies were listed on the A-share market, 15 of which were from the Sci-tech Innovation Board; in 2020, 42 pharmaceutical companies were listed on the Sci-Tech Innovation Board, accounting for over 60% of the shares.
Among them, Shengxiang Biology expects that its net profit in 2020 will increase by 70 times, from nearly 40 million yuan to 2.
8 billion yuan; Junshi Biology expects research and development expenses of 1.
8 billion yuan, and a huge net profit loss of more than 1.
5 billion yuan.
Entering 2021, Huitai Medical, Holobo, Zhijiang Biological, and Kangzhong Medical have taken the lead in listing on the Sci-tech Innovation Board.
36 IPOs including BeiGene, Shanghai Sailun Biological, and Sichuan Huiyu Pharmaceutical are on the way, with a total of RMB 100 billion.
After the "A split A" meeting of market value pharmaceutical companies, BeiGene is expected to become the first three-region listed pharmaceutical company.
.
.
The sci-tech innovation board pharmaceutical company may reach a new high.

 

　　Yuandong, Kexing.
.
.
26 pharmaceutical companies "snap the beach" sci-tech innovation board

 

　　The performance of pharmaceutical companies listed on the Science and Technology Innovation Board in 2020

　　Note: The total market value and the price increase and decrease are as of the close of trading on December 31, 2020

 

　　Sanyou Medical and SECCO are the 2020 performance bulletin

 

　　Shengxiang Biology: A surge of 70 times a year ! Net profit from 40 million to 2.
8 billion

 

　　In August 2020, Shengxiang Biotech officially landed on the Science and Technology Innovation Board.
The company is an in vitro diagnostic overall solution with independent innovative gene technology as the core, integrating R&D, production, and sales of diagnostic reagents and instruments, as well as third-party medical inspection services.
Solution provider.
According to the company's performance forecast, the net profit in 2020 is expected to be 2.
556 billion to 2.
806 billion yuan, a year-on-year increase of 6375% to 7008%, and the net profit in 2019 is nearly 40 million yuan.
Regarding the surge in performance, Shengxiang Biological said that the company actively responded to the global fight against the new crown epidemic, developed corresponding epidemic prevention and control products in a relatively short period of time, and simultaneously equipped professional after-sales and technical support teams to provide customers with comprehensive services in a timely and effective manner.
Fangfang's services have better met the needs of the global market, and the company's new crown nucleic acid detection reagents, nucleic acid detection equipment, related consumables and other products have a substantial increase in sales.
At the same time, the company's instrument sales and installed capacity growth further drove the company's incremental sales of all reagents.
In 2020, the company will ship 6,122 instruments in total.

 

　　Junshi Bio: Estimated research and development expenses of 1.
8 billion, and a huge loss of net profit exceeding 1.
5 billion

 

　　In July 2020, Junshi Bio was listed on the Science and Technology Innovation Board.
Data show that the company has been committed to the discovery, development, production and commercialization of innovative therapies since its establishment.
Not long ago, Junshi Biological released a performance forecast, predicting a net profit loss of 1.
644 billion yuan in 2020, a year-on-year decrease of 119.
96%, and a net profit loss of 747 million yuan in 2019.
Junshi Biology said that in 2020, the company's operating income will increase substantially, which can basically cover the company's product promotion and daily operating expenses in addition to R&D investment.
The company has continuously strengthened the marketing of its core product, Teriprolimab Injection (trade name: Tuoyi), expanded the number of first-line marketing personnel, increased investment in team building, and rapidly increased the product’s hospital coverage.
The sales revenue of Lizumab injection has gradually increased.
At the same time, the company's ability to transform research and development results has gradually emerged, and new foreign licensing income has been increased during the reporting period.
The net profit still suffered losses, mainly due to the company's increased investment in research projects and reserve R&D projects, and operating income could not fully cover R&D investment.
In 2020, the company's research and development expenses are expected to be approximately 1.
824 billion yuan, a year-on-year increase of approximately 92.
79%.
In 2020, the company will continue to enrich its product pipeline, continue to explore drug combination therapy, and rapidly promote the development of existing clinical projects and the development of reserve R&D projects, resulting in continuous growth of the company's R&D expenses.
As of the announcement date, the company's existing R&D pipeline has been expanded to 29 products under development, including 27 innovative drugs and 2 biosimilar drugs.
The company has carried out more than 30 clinical trials covering more than 10 tumor types, including 15 key registered clinical trials.

 

　　100 billion market value pharmaceutical companies "A split A" will have a meeting! The first three listed pharmaceutical companies may be born.
.
.
36 IPOs are on the way

 

　　Review status of the registration system for the science and technology innovation board of pharmaceutical enterprises

 

　　Entering 2021, pharmaceutical companies such as Huitai Medical, Hoobo, Zhijiang Biotech, and Kangzhong Medical have taken the lead in listing on the Sci-tech Innovation Board.
36 pharmaceutical companies including BeiGene, Shanghai Sailun Biotech, and Sichuan Huiyu Pharmaceutical have made IPOs.
On the way.
After the "A dismantling A" of 100 billion market capitalization pharmaceutical companies, BeiGene is expected to become the first listed pharmaceutical company in three places.
.
.
The science and technology innovation board pharmaceutical company is expected to reach new highs.

 

 

　　Recently, the official website of the Shanghai Stock Exchange Science and Technology Innovation Board disclosed BeiGene’s IPO prospectus (application draft).
The company plans to raise 20 billion yuan for drug clinical trial research and development projects, research and development center construction projects, production base research and development and industrialization projects, Marketing network construction projects and supplementary working capital.
According to data, BeiGene was listed in the United States and Hong Kong in 2016 and 2018 respectively.
If it can successfully land in A shares this time, it will become the first domestic pharmaceutical company to be listed in three places.

 

　　It is worth mentioning that last year, Lepu Medical, Changchun High-tech and many other A-share pharmaceutical companies announced plans to spin off their subsidiaries and go public on the Science and Technology Innovation Board, and there have been frequent good news recently.

 

 

　　A few days ago, Changchun Hi-tech, a white horse stock with a market value of 100 billion yuan, announced that its holding subsidiary, Beike Biotech Innovation Board, had an IPO.
According to the results of the deliberations of the meeting, Baike Biotech (first issue) meets the issuance conditions, listing conditions and information disclosure requirements.
Baike Biotech will carry out follow-up work in accordance with the relevant regulations and requirements of the China Securities Regulatory Commission and the Shanghai Stock Exchange.
According to the data, Baike Biotechnology is a high-tech biopharmaceutical company specializing in the research and development, production and sales of human vaccines.
Changchun Hi-tech stated that after the spin-off is completed, the company will still control Baike Biological.
The financial status and profitability of Baike Biological will still be reflected in the company's consolidated statements.
Although the spin-off will result in the dilution of the company's equity in Baike Bio-Technology, the development and innovation of Baike Bio-Bio will be further accelerated through this spin-off, which in turn will help improve the company's overall profitability in the future.
In January of this year, Changchun Hi-tech announced its 2020 performance forecast.
The estimated net profit is 3.
018 billion to 3.
195 billion yuan, an increase of 70% to 80% year-on-year.
One of the reasons for the performance growth is the revenue growth of the backbone pharmaceutical companies.

 

　

 

　　In December 2020, the IPO application of Lepu Diagnostics, a wholly-owned subsidiary of Lepu Medical, was accepted.
According to the data, Lepu Diagnostics' main business is the research and development, production and sales of in vitro diagnostic reagents and instruments.
The areas involved include blood diagnosis, POCT immunodiagnosis, molecular diagnosis and biochemical diagnosis.
At present, Lepu Diagnostics has formed an industrial layout with blood diagnosis and POCT immunodiagnosis related products as the core, and molecular diagnosis and biochemical diagnosis related products as the focus.
Lepu Medical said that after the spin-off is completed, it will further focus on the four main business sectors of medical equipment , medicine, medical services, and new medical care , focusing on cardiovascular patients , to further cultivate the cardiovascular medical market and enhance the competitiveness of the industry.
Lepu Diagnostics will become an independent in vitro diagnostic business listing platform of Lepu Medical.
By listing on the Science and Technology Innovation Board, it will broaden financing channels, enhance capital strength, enhance R&D capabilities and industry competitiveness, and thereby enhance Lepu Diagnostics' profitability.
A few days ago, Lepu Medical disclosed its 2020 performance forecast, with an estimated net profit of 1.
725 billion to 1.
984 billion yuan, a year-on-year increase of 0% to 15%.

 

　　Strictly control the entrance! China Securities Regulatory Commission and Shanghai Stock Exchange issued documents 4 times in 8 days

 

　　On January 28, the China Securities Regulatory Commission held a 2021 system work conference to summarize the work in 2020, analyze and judge the current situation, and study and deploy key tasks for the reform, development and stability of the capital market in 2021.
The meeting pointed out that it is necessary to scientifically and rationally maintain the normalization of IPO and refinancing, steadily develop the exchange bond market, improve the commodity and financial futures option product system; improve the evaluation standards of science and technology innovation attributes, strengthen the supervision of the shareholder information disclosure of the proposed listed companies , and effectively strengthen Supervision and risk prevention, resolutely prevent the disorderly expansion of capital; actively create conditions for the steady advancement of the market-wide registration system reform, strict delisting supervision, and expansion of multiple exit channels such as reorganization, restructuring, and active delisting.

 

　　On January 29, the China Securities Regulatory Commission issued the "Regulations on the On-site Inspection of Initial Issuers"; on February 1, the Shanghai Stock Exchange issued the "Shanghai Stock Exchange Science and Technology Innovation Board Issuance and Listing Review Business Guide No.
2-Information Disclosure and Verification Requirements for Frequently Asked Questions" Self-inspection Form; On February 3, the Shanghai Stock Exchange issued the "Shanghai Stock Exchange Science and Technology Innovation Board Issuance and Listing Review Rules Application Guidelines No.
1-On-site Supervision of Sponsorship Business".
On February 5th, the China Securities Regulatory Commission issued the "Guidelines for the Application of Regulatory Rules-Information Disclosure of Shareholders of Companies Applying for Initial Listings", focusing on regulating IPO chaos such as illegal holdings, surprise shareholdings, and multi-layer nesting; on the 7th, the exchange swiftly followed Further clarify the measures and applicable connection arrangements in the issuance and listing review.
The issuer and relevant intermediary agencies responded positively, expressing that they will earnestly implement the guidelines and do a good job in information disclosure and verification.

 

　　Industry analysts pointed out that the recent frequent announcements of regulatory policies have once again sent a signal of strict supervision.
With the continuous advancement of the registration system reform on the Science and Technology Innovation Board and the Growth Enterprise Market, the new IPO policy is just right, which will help prevent the disorderly expansion of capital and improve the quality of listed companies from the source.
In 2021, the speed of listing of companies will accelerate, and the number of IPOs and the rate of IPOs will continue to remain high.

 

　　Source: Oriental Fortune.
com, China Securities Regulatory Commission, Shanghai Stock Exchange official website, company announcement